The antitumour activity of luvometinib in patients with BRAF mutations was comparable to that of the BRAF inhibitor vemurafenib, which showed an ORR per PRC of 100% in patients with LCH or ECD harbouring BRAFV600 mutations.9 The gene discussed is BRAF; the disease is Langerhans cell histiocytosis.